Jose Goris, MD
General Practice · New York, NYNPI 1790714962
Payments from drug & device makers
Across 1,087 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- AstraZeneca$2K
- GSK$1K
- Novo Nordisk$1K
- Biohaven Pharmaceuticals, Inc.$1K
- plus $12K from 54 others
What the payments were for
- Consulting fees$1,2005%
- Food & beverage$21,52694%
- Education$1120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
- RECORLEV$273
- Reltone 200 Mg$250
- GLYCATE$250
- Reltone 400 Mg$250
- AIRSUPRA$249
- CAPLYTA$244
- BREZTRI$242
- Kerendia$239
- JARDIANCE$235
- RYBELSUS$222
- Omnipod$165
- TRULANCE$128
- VOQUEZNA$125
- VIVITROL$124
- GVOKE HYPOPEN$124
- Ozempic$106
How this compares
$22,838 in reported general payments places this provider in the 95th percentile of 5,764 general practice providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 366 | $368,896 |
| OzempicSemaglutide | 298 | $364,996 |
| FarxigaDapagliflozin Propanediol | 342 | $363,172 |
| JanumetSitagliptin Phos/Metformin Hcl | 221 | $281,085 |
| EliquisApixaban | 232 | $243,948 |
| TrulicityDulaglutide | 124 | $215,809 |
| JanuviaSitagliptin Phosphate | 186 | $206,620 |
| TradjentaLinagliptin | 175 | $164,912 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 155 | $151,200 |
| LinzessLinaclotide | 199 | $143,721 |
| RybelsusSemaglutide | 98 | $142,506 |
| VascepaIcosapent Ethyl | 223 | $141,838 |
| XareltoRivaroxaban | 78 | $96,639 |
| CreonLipase/Protease/Amylase | 44 | $89,694 |
| EntrestoSacubitril/Valsartan | 64 | $72,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Trijardy Xr, Synjardy | $804 | $638,201643 claims |
| Novo NordiskOzempic, Rybelsus | $1,441 | $507,502396 claims |
| MerckJanumet, Januvia | $391 | $487,705407 claims |
| AstraZenecaFarxiga, Lokelma, Breztri Aerosphere | $1,593 | $402,821387 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta, Anoro Ellipta | $1,469 | $284,608602 claims |
| AbbVieLinzess, Creon, Restasis | $3,209 | $278,009284 claims |
| PfizerEliquis, Abrysvo | $555 | $273,740339 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $91 | $252,550152 claims |
| Johnson & JohnsonXarelto | $292 | $96,63978 claims |
| NovartisEntresto | $892 | $72,70364 claims |
| Aimmune Therapeutics, Inc.Zenpep | $40 | $67,19928 claims |
| Astellas Pharma US IncMyrbetriq | $547 | $44,44068 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,764 general practice providers in New York.
Other general practice in New York
- Alejandra Gonzalez-DuarteNew York$519K
- Ronnie MyersNew York$464K
- Laila AkhlaghiNew York$52K
- Caroline CampbellNew York$50K
- Vezire SarakNew York$39K
- Yohan KimNew York$38K
- Christine SkordelesNew York$32K
- Bruce YaffeNew York$22K
- Joseph PantaleoNew York$14K
- Jeffrey ShapiroNew York$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.